Bioradiotherapy with Cetuximab May Reduce the Risk of Neck Node Relapse in Locoregionally Advanced Laryngeal Glottic Carcinoma: May HER1-Profile Be Useful in the Bioselection of Patients?

Furthermore, because of retrospective studies from comparable patient groups and settings indicating inferior disease control of RT plus cetuximab compared with RT plus cisplatin [ 19 ], patients inclusion in recent trials [ 15 , 20 ] was prematurely closed, and the primary endpoints OS did not reach statistical significance between the treatment groups in the first analysis of the study.

also in 111,027 other papers